Working… Menu

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03781479
Recruitment Status : Completed
First Posted : December 20, 2018
Last Update Posted : July 28, 2020
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 23, 2020
Actual Study Completion Date : July 23, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 6, 2021